A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor

RATIONALE: Schizophrenia is a complex neuropsychiatric disorder characterized, in part, by impaired dopamine signaling. TAK-063 is a selective inhibitor of phosphodiesterase 10A, a key regulator of intracellular signaling pathways that is highly expressed in the striatum. OBJECTIVE: Safety, tolerabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Max, Chrones, Lambros, Xie, Jinhui, Gevorkyan, Hakop, Macek, Thomas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063900/
https://www.ncbi.nlm.nih.gov/pubmed/27572830
http://dx.doi.org/10.1007/s00213-016-4412-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063900/
https://www.ncbi.nlm.nih.gov/pubmed/27572830
http://dx.doi.org/10.1007/s00213-016-4412-9

Ejemplares similares